Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.
Tomizawa D, Watanabe T, Hanada R, Horibe K, Horikoshi Y, Iwamoto S, Kinoshita A, Moritake H, Nakayama H, Shimada A, Taga T, Takahashi H, Tawa A, Terui K, Hori H, Kawano Y, Kikuta A, Manabe A, Adachi S. Tomizawa D, et al. Among authors: hanada r. Int J Hematol. 2015 Sep;102(3):318-26. doi: 10.1007/s12185-015-1825-x. Epub 2015 Jul 1. Int J Hematol. 2015. PMID: 26126642 Clinical Trial.
RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.
Sano H, Shimada A, Taki T, Murata C, Park MJ, Sotomatsu M, Tabuchi K, Tawa A, Kobayashi R, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Sano H, et al. Among authors: hanada r. Int J Hematol. 2012 May;95(5):509-15. doi: 10.1007/s12185-012-1033-x. Epub 2012 Mar 10. Int J Hematol. 2012. PMID: 22407852
High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, Tsuchida M, Horibe K, Tsukimoto I, Adachi S, Kojima S, Hayashi Y. Shimada A, et al. Among authors: hanada r. Int J Hematol. 2012 Oct;96(4):469-76. doi: 10.1007/s12185-012-1163-1. Epub 2012 Aug 23. Int J Hematol. 2012. PMID: 22915059
WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group.
Sano H, Shimada A, Tabuchi K, Taki T, Murata C, Park MJ, Ohki K, Sotomatsu M, Adachi S, Tawa A, Kobayashi R, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Sano H, et al. Among authors: hanada r. Int J Hematol. 2013 Oct;98(4):437-45. doi: 10.1007/s12185-013-1409-6. Epub 2013 Aug 27. Int J Hematol. 2013. PMID: 23979985
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Nakayama H, Tabuchi K, Tawa A, Tsukimoto I, Tsuchida M, Morimoto A, Yabe H, Horibe K, Hanada R, Imaizumi M, Hayashi Y, Hamamoto K, Kobayashi R, Kudo K, Shimada A, Miyamura T, Moritake H, Tomizawa D, Taga T, Adachi S. Nakayama H, et al. Among authors: hanada r. Int J Hematol. 2014 Aug;100(2):171-9. doi: 10.1007/s12185-014-1616-9. Epub 2014 Jun 25. Int J Hematol. 2014. PMID: 24961644
Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group.
Keino D, Kinoshita A, Tomizawa D, Takahashi H, Ida K, Kurosawa H, Koike K, Ota S, Iwasaki N, Fujimura J, Yuza Y, Kiyotani C, Yamamoto S, Osumi T, Ueda T, Mochizuki S, Isoyama K, Hanada R, Tawa A, Manabe A, Toguchi Y, Ohara A. Keino D, et al. Among authors: hanada r. Int J Hematol. 2016 Apr;103(4):416-22. doi: 10.1007/s12185-016-1937-y. Epub 2016 Jan 18. Int J Hematol. 2016. PMID: 26781613 Clinical Trial.
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Shimada A, et al. Among authors: hanada r. Blood. 2006 Mar 1;107(5):1806-9. doi: 10.1182/blood-2005-08-3408. Epub 2005 Nov 15. Blood. 2006. PMID: 16291592 Free article.
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group. Tomizawa D, et al. Among authors: hanada r. Pediatr Blood Cancer. 2007 Aug;49(2):127-32. doi: 10.1002/pbc.20944. Pediatr Blood Cancer. 2007. PMID: 16807916 Clinical Trial.
277 results